Global Non–Invasive Prenatal Testing Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
- 122 Pages
- Region: Global
Non-Invasive Prenatal Testing (NIPT) is the latest fetal chromosome screening technology. It can directly draw pregnant women's blood and detect whether the fetus has an abnormal chromosome number. NIPT can accurately screen down syndrome (Trisomy 21), Edward syndorme (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome. Monosomy X) and Klinefelter syndrome (XXY). The advantage of NIPT is that sampling is simple and safe. Pregnant women who have been pregnant for more than 10 weeks can draw blood directly to detect fetal aneuploidy and prevent abortion risk of amniocentesis.
Based on the Non–Invasive Prenatal Testing market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.
In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.
In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.
In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.
Key players in the global Non–Invasive Prenatal Testing market covered in Chapter 5:
PerkinElmer, Inc. (U.S.)
Thermo Fisher Scientific, Inc. (U.S.)
Koninklijke Philips N.V. (Netherlands)
F. Hoffmann-La Roche Ltd. (Switzerland)
Agilent Technologies, Inc. (U.S.)
Pacific Biosciences of California, Inc. (U.S.)
QIAGEN N.V. (Germany)
GE Healthcare (U.S.)
Beijing Genomics Institute (China)
Illumina, Inc. (U.S.)
In Chapter 6, on the basis of types, the Non–Invasive Prenatal Testing market from 2015 to 2025 is primarily split into:
Biochemical Screening tests
Cell-free DNA in Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
In Chapter 7, on the basis of applications, the Non–Invasive Prenatal Testing market from 2015 to 2025 covers:
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:
North America (Covered in Chapter 9)
Europe (Covered in Chapter 10)
Asia-Pacific (Covered in Chapter 11)
South America (Covered in Chapter 12)
Middle East and Africa (Covered in Chapter 13)
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025